ingrezza post strong quarter amid season headwind covid pandem net
sale report vs con go remaind year
see covid impact like long term pictur remain unchang
strong ingrezza sale trajectori next two year suggest survey
updat also provid program ongenti launch pipelin
ingrezza sale amid season dynam covid pandem
report net ingrezza sale vs estimate con
reflect trx absolut decreas trx q/q channel
inventori remov qs actual increas
reflect strong posit ingrezza sale midst
covid pandem season headwind consist survey covid
impact estim minim growth trajectori trend encourag
exit driven continu strength refil rate far apr howev
expect bigger impact covid crisi new patient start go
compani anticip patient visit also new patient visit would decreas
seen dramat drop-off management acknowledg new
prescript moder latest survey assess uptak ingrezza
indic covid would impact td pt get ingrezza prescript
significantli therefor trim net sale howev view
covid impact temporari strong ingrezza sale trajectori next two year
also suggest survey data
pipelin updat amid covid crisi program management note
present data phii poc studi adult
endo virtual meet june present includ full dataset includ
two biomark acth analys safeti data across cohort
conduct end phii meet fda march move ahead
single-arm pivot global trial start apr fda approv
ongenti opicapon adjunct therapi patient parkinson diseas
co postpon launch detail updat earli summer vy-aadc
gt prgm amend protocol start second pivot
trial addit initi ph ii studi
rare pediatr epilepsi also anticip
financi model updat report dilut ep
lower estimate con reflect higher expect sg
quarter due increas headcount cost invest td awar
campaign end report cash liquid invest
midst caus gener delay management revis sg expens
guidanc drive new pt
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
ingrezza approv tardiv dyskinesia peak
sale
orilissa approv endometriosi uterin
fibroid ww peak royalti
opicapon approv us file exist eu
data /canada peak sale risk-adj
better-than-expect uptak ingrezza tardiv
dyskinesia back sale forc expans dtc
orilissa uterin fibroid de-risk posit trial
proof-of-concept data congenit adren
hyperplasia support initi registr trial
orilissa fail demonstr efficaci
uterin
fibroid and/or lower expect uptak
opicapon approv
fail demonstr efficaci congenit
expect continu growth ingrezza moderate-to-
sever mild tardiv dyskinesia ye
market share lead teva austedo
expect continu growth orilissa moderate-
ye
patient/physician awar
model us approv orilissa uterin fibroid
risk discount
model us approv opicapon
data updat phii adult
endo meet june
mid updat registr program
adult follow discuss fda
launch updat orilissa endometriosi
initi vy-aadc pivot trial
initi trial
initi trial rare
pleas see import disclosur inform page report
reach previous pt base discount rate termin
growth rate exhibit valu neurocrin ingrezza elagolix acquir asset
opicapon ingrezza believ domest probability-adjust sale
achiev tardiv dyskinesia td orilissa elagolix model
launch endometriosi expect launch uterin fibroid
model ex-u launch orilissa begin well believ orilissa
achiev domest probability-adjust sale risk adjust
endometriosi uterin fibroid respect assum risk-discount
uterin fibroid note product market partner model
tier royalti net sale tier royalti ex-u net
sale believ opicapon end-of-dos motor fluctuat parkinson diseas
achiev /canada peak sale risk-adjust current
includ congenit adren hyperplasia valuat
repres addit upsid estim
compani data jefferi estim
clinic failur compani biotechnolog pharmaceut develop
treatment futur clinic failur lead delay approv possibl
discontinu program
regulatori failur fda could determin compani nda inadequ
could delay approv delay approv timelin could impact earn
commerci failur estim may reli success company/partn
receiv drug reimburs private/publ medic insur payer
financ risk may need rais addit fund support sg
activ current includ estim addit equiti rais howev
pleas see import disclosur inform page report
compani data jefferi estim
compani data jefferi estim
pleas see import disclosur inform page report
inc san diego-bas commercial-stag biopharmaceut compani focus develop
drug candid neurolog endocrin diseas neurocrin one market product ingrezza valbenazin
approv treatment tardiv dyskinesia compani second product orilissa elagolix partner
commerci approv treatment endometriosi pipelin includ product develop
parkinson diseas congenit adren hyperplasia rare/orphan endocrin diseas
pt dcf-base discount rate termin growth rate risk includ clinic regulatori commerci
biren amin certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
kelli shi phd certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
jeet mukherje phd certifi view express research report accur reflect person view
subject secur subject compani also certifi part compens directli indirectli
relat specif recommend view express research report
chang liu phd certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
case jefferi employe analyst respons coverag financi instrument discuss
report receiv compens base part overal perform firm includ invest bank incom seek
updat research appropri variou regul may prevent us asid certain industri report publish
period basi larg major report publish irregular interv appropri analyst judgement
articl articl
